Evercore ISI analyst Joshua Schimmer upgraded Neurocrine to Outperform from In Line with a $130 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine extends research collaboration with Sentia Medical Sciences
- Neurocrine price target lowered to $110 from $122 at RBC Capital
- Neurocrine price target lowered to $115 from $120 at Wells Fargo
- Neurocrine price target lowered to $127 from $132 at Cantor Fitzgerald
- Neurocrine price target raised to $131 from $125 at Wedbush